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Abstract: Myotonia congenita is a muscular disease characterized by myotonia, hypertrophy, and stiffness. It 
is inherited as either autosomal dominant or recessive known as Thomsen and Becker diseases, respectively. 
Here we confirm the clinical diagnosis of a family diagnosed with a myotonic condition many years ago and 
report a new mutation in the CLCN1 gene. The clinical diagnosis was established using ocular, cardiac, neuro-
logical and electrophysiological tests and the molecular diagnosis was done by PCR, SSCP and sequencing of 
the CLCNI gene. The proband and the other affected individuals exhibited proximal and distal muscle weak-
ness but no hypertrophy or muscular pain was found. The myotatic reflexes were lessened and sensibility was 
normal. Electrical and clinical myotonia was found only in the sufferers. Slit lamp and electrocardiogram tests 
were normal. Two affected probands presented diminution of the sensitive conduction velocities and prolonged 
sensory distal latencies. The clinical spectrum for this family is in agreement with a clinical diagnosis of Becker 
myotonia. This was confirmed by molecular diagnosis where a new disease-causing mutation (Q412P) was 
found in the family and absent in 200 unaffected chromosomes. No latent myotonia was found in this fam-
ily; therefore the ability to cause this subclinical sign might be intrinsic to each mutation. Implications of the 
structure-function-genotype relationship for this and other mutations are discussed. Adequate clinical diagnosis 
of a neuromuscular disorder would allow focusing the molecular studies toward the confirmation of the initial 
diagnosis, leading to a proper clinical management, genetic counseling and improving in the quality of life of 
the patients and relatives. Rev. Biol. Trop. 56 (I): 1-I I. Epub 2008 March 31. 
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The term myotonia refers to a feature 
of the skeletal muscle mechanics, which is 
characterized by a lengthening in the muscle 
relaxation time that occurs after a voluntary 
or mechanical stimuli, resulting in a transitory 
failure to complete the antagonic movement 
(Morales et al. 2003). Diseases associated with  
this symptom are collectively termed myoto-
nias and accordingly to their clinical features, 
they are classified into: 1-dystrophic myotonias 
and 2-non-dystrophic myotonias. Myotonic 
dystrophy type 1 (DM1) and 2 (DM2), the most 
common muscular problem in young adults, 
belong to the first group, whereas the sodium 
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channelopathies and the chloride channelopa-
thies or myotonia congenita belong to the sec-
ond (reviewed in Morales and Cuenca 2004). 
Myotonia congenita (MC) is a hereditary 
muscular disease, electrophysiologically char-
acterized by presenting increased excitability 
of the muscular fiber, which is due to repetitive 
action potentials of the muscle membranes, 
which is reflected in clinical myotonia, mus-
cular stiffness and hypertrophy (Meyer-Kleine 
o al. 1995, Zhang et al. 1996). The clinical 
phenotype depends partially on whether the 
disease is inherited as autosomal dominant, 
(termed Thomsen disease) or as an autosomal 
recessive generalized myotonia (termed Becker 
disease). However, the latter is clinically more 
severe and more common (Sun et al. 2001). 
The two disorders differ clinically by the age 
of onset, spreading of the myotonia, a typi-
cal transient muscular weakness only present 
in the recessive trait and genetically by their 
transmission pattern (Koch et al. 1992, Koch 
et al. 1993). 
Onset of myotonia congenital (Thomsen 
and Becker disease) is early in childhood (dur-
ing the first or second decade of life), but usu-
ally earlier in Thomsen disease (Nagamitsu et 
al. 2000, Jurkat-Rott et al. 2002, Heatwole and 
Moxley 2007). Muscular stiffness can affect 
every skeletal muscle in the body, but is amel-
iorated by exercise (warm-up phenomenon). 
It can be associated with transient weakness 
during quick movements lasting only seconds 
or as long as thirty minutes in Becker dis-
ease (Jurkat-Rott et al. 2002). Nevertheless, 
myotonia in MC is clinically highly variable, 
ranging from only EMG detectable myotonic 
discharges to disabling muscle stiffness at an 
early age (Sun et al. 2001). 
The two diseases are associated with muta-
tions in the CLCNI gene, located in chromo-
some 7q35. The CLCNI gene has 23 exons and 
encodes the skeletal muscle chloride channel 
protein (CLC-1) with 18 a-helix domains, 
some of these being transmembrane domains 
(Koch et al. 1992). CLCNI is a voltage-gate 
dependent channel belonging to the CLC fami-
ly of chloride channels, of which nine members 
2 
have been identified thus far (Grunnet et al. 
2003). This channel is a complex homodimer 
that conducts chloride ions over the entire 
physiological voltage ranges and is conse-
quently the major mediator of chloride con-
ductance in the skeletal muscle (Esteban et 
aL 1998, Zhang et al. 2000b, Jurkat-Rott et 
al. 2002). The intensive search for mutations 
that followed its discovery showed that the 
dominant form is very rare, since very few 
different families (-14 families) have been 
shown to present a clear dominant inherit-
ance pattern (reviewed in Colding-Jorgensen 
2005). The recessive form is more common, 
with a frequency of —1:23 000. Males seem to 
be affected predominately over females with 
a ratio of 3:1 only when the typical clinical 
features are taken into account. However, fam-
ily studies indicate that women are affected 
at the same frequency, although to a much 
lesser degree (Lehmann-Horn and Jurkat-Rott 
1999). Eighty different CLCNI mutations have 
been associated with MC (Colding-Jorgensen 
2005). The majority of these mutations are 
found in the recessive form (Becker disease), 
whereas only a few have been described with 
the pure dominant form (Thomsen disease) 
(Pusch 2002, Colding-Jorgensen 2005). A clear 
distinction between dominant and recessive 
mutations is not always possible, since several 
mutants have been described in both recessive 
and dominant traits (Meyer-Kleine et al. 1995, 
Koty et aL 1996, Sun et al. 2001, Pusch 2002, 
Colding-Jorgensen 2005). 
It was originally suggested that the chlo-
ride channel was a dimer with an unusual 
structure; two independent pores forming a 
so-called "double-barrel", with two independ-
ent fast-gating mechanism and one slow-gating 
mechanism (Grunnet et al. 2003). X-ray data 
have elucidated the structure of the chloride 
channel (Dutzler et al. 2002), however little is 
known about the structure/function relationship 
of Cl channel (Jurkat-Rott et al. 2002). The 
"double-barrel" model proposed by this study 
can explain the dual inheritance of congenital 
myotonic mutations in a recessive or dominant 
manner (Grunnet et al. 2003). 
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The aim of our study was to establish the 
clinical and molecular diagnosis of a Costa 
Rican family that had not had an adequate 
clinical diagnosis since the first cases in the 
family appeared. Here we report clinical and 
molecular data from a family carrying a new 
mutation in the CLCNI gene causing Becker 
disease and discuss the possible implications of 
the mutations and the function-structure-phe-
notype relationships in the CLCNI channel. 
MATERIALS AND METHODS 
Patients: the study involved nine mem-
bers of the family shown in Fig. IA, in which 
the proband had been previously diagnosed 
with a myotonic condition, to know, myo-
tonic dystrophy type I (DM1), but they were  
negative for the DM1 mutation (Morales et al. 
2001). The proband (11.6, Fig. IA), who was 20 
years old at the time of this study, had failed to 
crawl by the time she was two years old. She 
experienced problems climbing stairs and her 
symptoms evolved into an important motor 
compromise. She developed limb distal muscle 
weakness, myotonia in tongue and hands, 
atrophy of the limbs, muscular contractures 
that made walking difficult, contractures in her 
hips and with a positive EMG, which detected 
typical myotonic discharges. The two affected 
siblings (11.8 and 11.9, Fig. lA) had similar 
symptoms to the proband, except milder and 
with an age of onset of about five years old. 
All of the family members were brought to the 
Costa Rican capital from their homes in order 
to accomplish more detailed clinical studies, 
which allowed us to establish a more accurate 
Fig. I. Pedigree and SSCP analysis of the Costa Rican family with Becker disease. (A) Pedigree of the family affected by 
Becker disease. Squared symbols indicate men and round symbols indicate women. Empty symbols denote healthy individu-
als and dark filled symbols denote affected individuals. The arrow indicates the proband in the family. A positive EMG is 
indicated as e+. (B) SSCP analysis of the family members analysed in this study. PCR products were solved using silver 
stain protocol. An aberrant band pattern was found only in exon I I and only in the affected patients in this family. The arrow 
shows the absence of a conformer in the proband and the affected siblings. 
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clinical diagnosis. Accordingly to our data, 
there is no known consanguinity in the family. 
Signed informed consent was obtained for all 
subjects for the clinical and molecular investi-
gation in accordance with the ethical protocols 
approved by the Ethical Scientific Committee 
of the University of Costa Rica. 
Clinical diagnosis: the clinical diagnosis 
was established after physical and electrophysi-
ological tests. The EMG was carried out on 
eight members of the family and the slit lamp 
test was performed on two affected patients 
(11.8 and 11.9), in order to exclude the possibil-
ity that they were affected by DM1. In addition 
to this, an EKG was done to all patients and the 
levels of CPK were also determined. 
Clinical and electrophysiological exami-
nation: a complete neurological evaluation of 
all patients focused on muscles, analyzing the 
strength, the presence of the myotonic phenom-
enon before the muscular percussion and in the 
relaxation phase after a voluntary contraction. 
The muscular strength was recorded according 
the Medical Research Council scale. In addi-
tion, we developed a conventional and quantita-
tive EMG study, with a motor neuroconduction 
study, including distal motor latency, motor 
nerve conduction velocities, F-M latencies and 
extent of the action potential of the median, 
ulnar, tibial and peroneal nerves. We also 
measured sensory nerve conduction velocities 
and sensory nerve action potentials of the right 
median, ulnar and sural nerves. All tests were 
performed at skin temperature of 31 °C. 
PCR of the CLCN1 exons: genomic 
DNA samples form nine members of the fam-
ily, obtained from peripheral blood leukocytes 
were used for PCR amplification of the 23 
exons covering the entire coding sequence of 
the CLCNI gene. The intronic primers sets 
and PCR reaction conditions were described 
elsewhere (Lehmann-Horn et al. 1995). The 
experimental conditions were optimized for 
each primer. Each reaction had a final volume 
of 50 µ1 containing: 100 ng of DNA, 50 pmol  
of each PCR primer, 50 mM of each deoxy-
nucleotide triphosphate, 10 mM Tris (pH 8.3), 
50 mM KCL, 1.5 mM MgC12 and 0.5 units of 
AmpliTaq polymerase. Amplification condi-
tions were as follow: denaturation at 96 °C for 
5 min: 35 cycles at 96 °C for 30 s, 55 °C for 45 
s, and 72 °C for 1 min followed by a terminal 
elongation at 72 °C for 5 min (Lehmann-Horn 
et al. 1995). 
SSCP and sequencing: the PCR products 
of the 23 CLCNI exons were analyzed for SSCP 
conformers as previously described (Orita et al. 
1989). The PCR products were denatured and 
then loaded on 6 % nondenaturing polyacryl-
amide gels and electrophoresis was carried 
out as previously described (Nagamitsu et al. 
2000). The products were detected using the 
silver stain protocol. Direct PCR sequencing 
was performed for the aberrant PCR product 
on the SSCP analysis. Samples were purified 
using Qiagen Spin-30 columns and both strands 
were sequenced by a dideoxi-termination 
method using the BDT (Big Dye Terminator) 
Sequencing Kit 3.0 (Perkin Elmer) and the ABI 
PRISM 377 DNA sequencer. Sequences were 
analyzed with the BioEdit 5.0.9 program (Ibis 
Therapeutics Carlsbad, CA92008). 
Allele-specific restriction digestion: Tasi 
restriction sites were used for allele-specific 
restriction digestion of the exon 11 mutation in 
all family members and in 100 other samples 
from healthy individuals or with a disease other 
than MC, in order to confirm that the amino 
acid changed is the causing-disease mutation. 
The mutation abolishes the Taal restriction site 
generating size fragments of 50, 59 and 109 
bp in heterozygous carriers and 50 and 59 pb 
bands in non-carriers of the mutation, thus the 
109 bp fragment indicates the presence of the 
mutation. Genomic DNA (150 ng) from all of 
the samples was amplified for exon 11 using 
the conditions described above. Amplified 
products were digested with ten units of the 
restriction enzyme overnight according to the 
manufacturer instructions. The digestions were 
analyzed by electrophoresis in nondenaturing 
4 	 Rev. Biol. Trop. (Int. J. Trop. Biol. 1SSN-0034-77441 Vol. 56 (1 ): 1-11, March 2008 
5% acrylamide gel, using 0.6X Iris-borate/ 
EDTA (TBE) and bands were solved using the 
silver stain protocol. Gels were run at 200V for 
3 h at room temperature. 
RESULTS 
Clinical picture of the family members: 
the study was done when the family members 
were between 12 and 20 years old (mean of 
15.6) with an age of onset of the main symp-
toms between 2 and 5 years of age (without 
taking into account the crawl problems in the 
first few months). The proband complained 
of difficulty in initial movements, on get-
ting up in the mornings or after prolonged 
resting period, but after a while the move-
ments improved (the warm up phenomenon). 
The three affected patients showed lessened 
reflexes, and the proband showed the steppage 
gait. Sensory examination was completely 
normal in all such family members and they 
showed clinical myotonia in different parts 
of their bodies. The three affected patients 
showed distal weakness, and two of them (11.6 
and 11.8) had also proximal weakness of the 
lower limbs with no pain at all in the affected 
patients. The proband also showed atrophy 
in the forearm and discreet peroneal atrophy. 
The rest of their relatives were normal. The 
slit lamp test performed in two affected mem-
bers of the family was normal. Furthermore, 
they showed normal pupil reflexes. The EKG 
results were normal for all of the patients, and 
there was no family history of cardiac prob-
lems, arrythmias or other cardiac complica-
tion. CPK levels were mildly increased in the 
proband and in one of her sisters (11.9). 
Electrophysiological examination: the 
EMG test was positive in the three affected 
patients, showing the classical myotonic runs 
and discharges together with the typical myo-
phatic pattern. In the quantitative study, two of 
them (11.8 and 11.9) showed a discrete diminu-
tion on the potentials amplitude with reduced 
duration, limited fibrillations, an early and 
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complete recruitment with low amplitude in 
the full effort and with a normal polyphasia 
percentage. In the proband, the quantitative 
EMG showed motor unit potentials with high 
amplitude, duration and polyphasia percent-
age. Two patients (11.6 and 11.8) presented 
diminished sensory conduction velocities and 
prolonged sensory distal latencies of the sural 
nerve. The rest of their relatives did not present 
electrical or clinical myotonia. 
The molecular testing for myotonic dys-
trophy type 1 (DM1) was negative in this fam-
ily (Morales et al. 2001). The phenotype was 
consistent with a clinical diagnosis of myotonia 
congenita, Becker disease. We carried out a 
further investigation of the CLCNI gene by 
SSCP analysis. 
SSCP analysis, sequencing of aberrant 
SSCP conformers and allele-specific restric-
tion digestion: after screening all of the 23 
exons in the CLCNI gene by SSCP, we found 
an aberrant SSCP conformer in exon 11 in 
the three affected patients (Fig. 1B) of the 
family in study (Fig. 1A). The band pattern 
observed in the SSCP analysis in the other 
members analysed of the family was the same 
as the control (Fig. 1B). Direct sequencing of 
the PCR product of exon 11 showed a new 
mutation, an A-to-C base change at nt 1235 
(exon II ), which resulted in a substitution of 
glutamine for proline at codon position 412 
(Q4 I 2P) (Fig. 2). Abolition of a Tasl restriction 
site due to the A-to-C base change at nt 1 235 
provided a quick assay for this new mutation in 
exon 11 (Fig. 3). Tasl digestion generated frag-
ments of 109 bp and 50 bp in the three affected 
patients who resulted homozygous for the new 
mutation (Fig. 3), and of 50 bp and 59 bp in 
normal healthy subjects (Fig. 3). Digestion of 
DNA with Tasl in the other family members 
showed that all of them are heterozygous car-
riers of the new mutation. The assay in these 
samples generated the three expected bands 
for a heterozygous, at 109, 59 and 50 bp (Fig. 
3). This new mutation was not found in 200 
normal chromosomes. A comparison of CLC-1 
channel sequences of various species showed 
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	Control 
	 that the glutamine at codon position 412 is 
	
Met 
	
Gly 	 Gln 	 Phe 
	 highly conserved (Fig. 4). 
ATG G G T CA A T TCA 
70 	 80 
Proband 
Met 	 Gly 	 Pro 	 Phe 
ATGGGTCCAT TCA 
70 
Fig. 2. Sequence analysis of exon 11 region where the 
new mutation is located. The figure compares the exon 
11 sequences obtained from a healthy control and the 
proband of this family. The arrows indicate the 1235 
A-to-C nucleotide change in exon 11 (Q4I2P) that 
changes the amino acid sequence between the control 
and proband. 
DISCUSSION 
Inherited disorders that present myoto-
nia as a major sign include DM1 and DM2, 
chloride channelopathies or myotonia con-
genita (Thomsen and Becker diseases) and 
sodium channelopathies (paramyotonia con-
genita, potassium-aggravated myotonia and 
hyperkalemic periodic paralysis) (reviewed in 
Morales and Cuenca 2004). 
According to the clinical results obtained 
in this study, we concluded that the clinical pic-
ture of this family is compatible with myotonia 
congenita, and its autosomal recessive inheri-
tance pattern suggested the diagnosis of Becker 
disease. This is the first clinical report in Costa 
Rica of a family affected with Becker disease, 
but the second regarding a non-dystrophic 
myotonic condition (Morales et al. 2003). The 
table 1 presents a comparison between myo-
tonic dystrophy and myotonia congenita based 
on the information from Harper (2001), Koty et 
al. (1996), Zhang et al. (1996), Lehmann-Horn 
and Jurkat-Rott (1999), Meola (2000), and 
through the personal experience. 
The molecular diagnosis obtained in this 
study confirmed the clinical diagnosis of this 
family, besides of the identification of a new 
mutation on the CLCNI gene, enlarging the 
spectrum of mutations in this gene. The fact 
1.1 
	
1.2 	 11.3 	 111.2 	 11.5 	 11.6 	 11.7 	 11.8 	 11.9 	 Cl 	 C2 	 C3 	 C4 	 C5 	 M 
109 by 
59 bp 
200 by 
150 by 
100 by 
50 by 
Fig. 3. Restriction enzyme assay that detects the new mutation in exon 11 of the CLC-1 gene. PCR products were digested 
with Tasl to confirm the new mutation in the family. The first 9 lanes (I.1-II.9) show digested PCR products from the fam-
ily members. The next 5 lanes (C1-05), represent controls and the last lane (M) is a 50 bp ladder marker. The sizes of the 
digested products are indicated. 
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Human CLC-1 401 
Cimp CLC-1 402 
Dog 	 CLC-1 401 
Mouse CLC-1 401 
Rat 	 CLC-1 401 
419 
420 
419 
419 
419 
Fig. 4. Alignment of the CLC-1 chloride channel among different species in the region of the exon II mutation. The 
BoxShade program was used to show the similarities and differences in the sequence between species. AA residue identi-
ties are marked with a black background and similarities are marked with a grey background. The species involved in this 
analysis included Homo sapiens (Human), Pan troglodytes (Chimp), Mus musculus (Mouse), Raffia norvegicus (Rat), Canis 
famillaris (Dog). Note that glutamine residue at position 412 is highly conserved among species. 
TABLE 1 
Differences and similarities between dystrophic and non-dystrophic myotonias 
Dystrophic myotonias 	 Non-dystrophic myotonias 
DM I 	 DM2 	 Thomsen disease 	 Becker disease 
Muscular atrophy 
Hypertrophy 	 ++ 	 -H- 
Stiffness 	 + 
Muscular weakness 	 + 	 + 
Facial muscular weakness 	 -H- 	 + 
Weakness of the muscles in the jaws 	 -H- 	 + 
Proximal muscular weakness of the legs 
	 (+) 	 + 	 + 
Distal muscular weakness of the limbs 
	
++ 	 ++ 
Muscular degeneration 	 + 	 + 
Electrical myotonia (EMG) 	 +-F 	 + 	 + 
Physical myotonia 	 ++ 	 ++ 	 -i- 
Cardiac problems 
	
-H- 	 ++ 
Progression of the disease 	 -i-i- 	 + 
Ptosis 	 + 
Cataracts 
	 + 	 + 
Frontal balding 
	 + 
Hatched face 
	 + 	 + 
Mental retardation 	 + 	 (+) 
Other systems 	 1-i- 	 ++ 
Muscular pain 	 + 	 + 
Age of onset 	 Young adult Young 
	 adult 	 Childhood 	 Childhood 
Congenital form 	 + 	 ? 
Inheritance pattern 	 Autosomal 	 Autosomal Autosomal dominant 
	 Autosomal recessive 
dominant 	 dominant 
Anticipation 	 (÷) 
+ finding present; ++ finding present and prominent; (+) finding present but milder; - finding no present; ? unknown 
Rev. Biol. Trop. (Int. J. Trop. Bid. ISSN-0034-7744) Vol. 56 41): 1-11, March 2008 
	 7 
that the genotype of the affected patients cor-
relates with their phenotypes, that the muta-
tion was absent in 200 normal chromosomes 
and that the Q412P mutation affects a residue 
conserved among most members of the CLC 
channel family (Mailander el al. 1996) and 
among different species, suggest that this is 
the disease-causing mutation. Also, our data 
suggest that this is a rare mutation and prob-
ably restricted to the Costa Rican population. 
However, although our clinical data indicate 
the there is no consanguinity in this family, 
haplotype studies would be required in order to 
explore the possibility of identity-by-descents 
or of founder events for this mutation in the 
Costa Rican population. This would eventu-
ally suggest that this mutation is an ancestral 
mutation and that parents are, in some degree, 
related. Unfortunately, at the moment we do 
not have the haplotype analysis data, but it is 
something that needs to be done, not just for 
this mutation but also for the other ones we 
have been obtaining in other MC families (data 
not showed). The evidence that would confirm 
that this is the disease-causing mutation can be 
obtained through functional analysis studies of 
this new mutation, something that is expected 
to develop in a near future. 
It is known that several mutations are 
associated with a particular inheritance pattern 
in the myotonia congenita. Some mutations are 
associated with the recessive form meanwhile 
others are associated with the dominant form. 
However, there are a few mutations that can 
behave as recessive or dominant, which is 
probably because of the genetic background in 
every patient (Meyer-Kleine et al. 1995, Koty 
et al. 1996, Pusch 2002, Colding-Jorgensen 
2005). However, the relationships between 
different mutations and its inheritance pattern 
and a particular phenotype, both within and 
between a given set of different families having 
the identical mutation still requires clarification 
(Heatwole and Moxley 2007). The list of muta-
tions already described in the CLCNI gene is 
important as a starting point in the molecular 
characterization of the new families that appear 
in the future. The new mutation we report here,  
the Q4 1 2P behaves as recessive, which is con-
sistent with the inheritance pattern and the phe-
notype in the family, where the members who 
were heterozygous for this mutation showed no 
myotonia, but the homozygous members were 
affected and showing the Becker phenotype. 
Nonetheless, for many mutations in the CLCNI 
gene, it is still required to understand in a better 
way the genotype—phenotype relationships in 
MC in order to offer a proper clinical manage-
ment and genetic counseling. 
In 1996, Mailander et al. (1996), reported 
that clinically unaffected heterozygous males, 
but no females, presented latent myotonia in six 
families affected with Becker disease, however, 
our clinically unaffected heterozygous males 
(1.2 and 11.4, Fig. 1A) did not show latent myo-
tonia, meaning that not all of the mutations that 
cause the recessive form of the disease trig-
gers latent myotonia, and this agrees with the 
fact that no other recessive mutation has been 
associated with latent myotonia. However, it is 
interesting to notice that our mutation (Q412P) 
is one amino acid away form another recessive 
mutation (F413C), first reported by Koch et 
al. (1992), then by Zhang et al. (2000a) who 
studied the functional consequences of this 
mutation and did not find the presence of latent 
myotonia, but also three amino acids away 
from one recessive mutation reported to cause 
latent myotonia (A415V) (Fig. 2) (Mailander 
et al. 1996). Thus, the ability of the mutation 
to cause latent myotonia could be intrinsic 
of the amino acid that is changed and that is 
capable to produce a stronger effect than the 
other mutations. For instance, in the A415V 
mutation, valine has considerably more bulk 
than alanine, something that does not happen 
with the other mutations, therefore producing a 
more steric effect that could affect the channel 
structure and in some way its function, even in 
the heterozygous state. 
Members of the CLC family of voltage-gat-
ed chloride channels are found from bacteria to 
mammals with considerable degree of conserva-
tion in membrane-inserted, pore-forming region. 
The crystal structures of the CLC channels of 
Escherichia coil and Salmonella typhimurium 
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provided a structural framework for the entire 
family. The CLC channels are homodimeric pro-
teins with an overall rhombus-like shape. Each 
CLC dimer has two independent pores each 
contained within a single subunit, a so-called 
double barrel model. The CLC subunit consist of 
two roughly repeated halves that spans the mem-
brane in opposite orientations. This antiparallele 
architecture defines a chloride selectivity filter 
within a 15-A neck of an hourglass-shaped pore. 
Three Cr binding sites within the selective 
filter stabilize ions by interactions with a—helix 
dipoles and by chemical interactions with nitro-
gen atoms and hydroxyl groups of residues in 
the protein. The CF binding site nearest to the 
extracellular solution can be occupied either by 
a Cl or by a glutamate carboxyl group where 
this glutamate work as a group that closes the 
pore by mimicking a CI— ion (Dutzler 2004a). 
The channels have a complex gating behaviour, 
in which channel opening and closing are tightly 
coupled to ion permeation. In the closed confor-
mation of the channel, the conserved glutamate 
residue occupies one of the ion-binding sites; 
on the channel opening, this glutamate residue 
moves out of the binding site, thereby making 
room for an additional CI ion ( Dutzler et al. 
2003, Dutzler 2004b). 
Our mutation and others in the same 
region are located between the transmembrane 
a—helix domains K and L (Dutzler et al. 2002), 
region that has not been properly characterized; 
only the filter selective has been largely char-
acterized (Dutzler 2004a, Dutzler 2004b). The 
only mutation functionally characterized on 
this region is the F413C (Zhang et al. 2000a). 
Zhang et al. (2000a) developed such a study 
and they found that this mutation could lead 
to a decrease in the macroscopic chloride cur-
rents and hyperexitability in the skeletal muscle 
membranes. The significance of this change 
for myotonia congenital, however, is uncertain. 
They also propose that this mutation may affect 
folding, assembly or trafficking of CLCN1 
channel proteins. It is important to expand 
these studies to examine other mutations in  
this domain. By comparing the phenotypes 
caused by each mutation it may be possible to 
determine the specific function of this domain 
in the protein. 
Perhaps some domains are more important 
because they stabilize the channel to allow a 
proper Cr conductance. Mutations at or near 
the selective filter for example, could have a 
major impact on the CF conductance. Grunnet 
et al (Grunnet et al. 2003) reported two domi-
nant mutations that show this effect. They pro-
pose that the M 128V mutation appears to be 
located in the homomeric interaction domain of 
CLCN1, and therefore is suspected to influence 
the dimerization. Further, the E193K mutation, 
which is located next to the selective filter, intro-
duces a selective shift in the CLCNI channel, 
which may explain the altered selectivity of this 
mutant. Both mutations behave in a dominant 
manner with a rightward shift in the current-
voltage relationship, which results in reduced 
CLCNI currents at physiological relevant poten-
tials. Thus, it is possible that the inheritance pat-
tern of some mutations in the CLCNI gene can 
be explained by the position of the mutation and 
their effect in the function-structure relationship 
of the most important domains of the channel 
that regulate the Cr conductance. 
The family we report here seems to rep-
resent a typical example of Becker disease: 
non-progressive, non-disabling and probably 
not as severe as other families affected with this 
disease. However, by studying the functional 
consequences of this new mutation, we may 
be able to provide a better understanding of 
the phenotype of the affected members. This 
could provide an explanation for the diminu-
tion of the sensitive conduction velocities and 
prolonged sensory distal latencies and other 
features in this family. It may also be possible 
to find a function for the region where the 
mutation is and to establish a better phenotype-
genotype correlation, which could help us to 
better understand the structure-function-geno-
type relationships of the different mutations in 
the CLCNI gene. 
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RESUMEN 
La miotonia congenita es una enfermedad muscular 
caracterizada por miotonia, hipertrofia y rigidez. Se pre-
senta con dos patrones de herencia, autosOmica dominante 
en cuyo caso recibe el nombre de miotonia de Thomsen, o 
autosOmica recesiva conocida como miotonia de Becker. 
En este trabajo se confirm° el diagnostico clinico pre-
suntivo hecho hace algunos altos en una familia con una 
condicidn miotonica y se reports una nueva mutacion en 
el gen CLCNI. El diagnostico clinico se establecio desputs 
de estudios oculares, cardiacos, neurologicos y electrofi-
siologicos. El diagnostico molecular fue hecho mediante 
la PCR, SSCP y secuenciacion del gen CLCNI. El caso 
indite y los otros individuos afectados exhibieron debilidad 
muscular proximal y distal, pero no se encontro hipertrofia 
ni dolor muscular. Los reflejos miotaticos estuvieron dismi-
nuidos y la sensibilidad fue normal. Se encontro miotonia 
clinics y electrica solo en los individuos afectados. Las 
pruebas de lampara de hendidura y electrocardiograma 
resultaron normales. Dos individuos afectados presentaron 
disminuciOn de las velocidades de conduction sensitiva y 
latencias distales sensoriales prolongadas. El cuadro clinico 
eonenerda eon la miotonia de Becker, lo curd se confirrn6 
con el hallazgo de una mutaciOn responsible de la enfer-
medad en el gen CLCNI (Q4I2P), la cual se encontro en la 
familia y estuvo ausente en 200 cromosomas provenientes 
de la poblacian general. No se encontro miotonia latente, 
por lo que probablemente la habilidad de causar este sign 
subclinico es intrinsica de cads mutaciOn. Afinar el diag-
nostic° clinico diferencial de las enfermedades neuromus-
culares permitiria enfocar los estudios moleculares hacia la 
confirmation del diagnostic° initial en forma eficiente, lo 
cual permitirla un manejo clinico y asesoramiento genetico 
mas adecuados y una mejora en la calidad de vida de los 
pacientes y sus familial. 
Palabras chive: miotonia congenita, distrofia miotonica, 
miotonia de Becker, canalopatia de cloruro, SSCP. 
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